Related Experiment Video
Updated: Jul 13, 2026
06:38
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
Receptor expression in orbital inflammatory syndromes and implications for targeted therapy
V H Ho1, P Chevez-Barrios, J L Jorgensen
1Section of Ophthalmology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Tissue Antigens
|July 6, 2007
Summary
Orbital inflammatory syndromes show strong expression of CD20 and CD25 targets. These findings suggest potential new therapies like rituximab and denileukin diftitox for future clinical trials.
Area of Science:
- Ophthalmology
- Immunology
- Pathology
Background:
- Orbital inflammatory syndromes (OIS) encompass a diverse group of conditions affecting the eye socket.
- Identifying specific molecular targets within OIS tissues is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the expression of multiple therapeutic targets, specifically CD antigens, in tissue specimens from patients with OIS.
- To evaluate the potential of CD20 and CD25 as targets for novel OIS treatments.
Main Methods:
- Retrospective review of 16 OIS patient records with available tissue blocks.
- Immunohistochemical staining of archived specimens for CD3, CD20, CD22, CD23, CD25, and CD52 antigens.
- Histologic diagnosis confirmation and staining pattern agreement by collaborating pathologists.
Main Results:
- CD20 was strongly expressed in most OIS specimens, with exceptions in Wegener's granulomatosis, eosinophilic granuloma, and nonspecified granulomatous inflammation.
- CD25 was also strongly expressed in most OIS specimens, with moderate expression in Wegener's granulomatosis.
- Both CD20 and CD25 demonstrated significant expression across various OIS subtypes.
Conclusions:
- CD20 and CD25 are highly expressed in most orbital inflammatory syndromes.
- Rituximab (targeting CD20) and denileukin diftitox (targeting CD25) show promise as future therapeutic agents for OIS.
- Further validation in larger studies is recommended to confirm these findings for clinical trial consideration.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
01:26Signal Transduction: Overview
Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Typically, signal transduction involves three...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes: